Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
8,677
Views
88
CrossRef citations to date
0
Altmetric
Coronaviruses

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies

Xun Wanga State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Xiaoyu Zhaoa State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Jieyu Songb Department of Infectious Diseases, Huashan Hospital affiliated with Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Jing Wub Department of Infectious Diseases, Huashan Hospital affiliated with Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yuqi Zhuc State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Minghui Lia State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yuchen Cuia State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yanjia Chena State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Lulu Yanga State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Jun Liuc State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China;d Fubio (Suzhou) Biomedical Technology Co., Ltd., Suzhou, People’s Republic of ChinaView further author information
,
Huanzhang Zhuc State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Shibo Jiange Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of ChinaView further author information
&
Pengfei Wanga State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China;c State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2454-7652View further author information
ORCID Icon show all
Pages 477-481 | Received 27 Dec 2021, Accepted 12 Jan 2022, Published online: 04 Feb 2022

References

  • He X, Hong W, Pan X, et al. SARS-CoV-2 Omicron variant: characteristics and prevention. MedComm. 2021;2:838–845.
  • Davies NG, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055.
  • Mlcochova P, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114–119.
  • Wang P, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135.
  • Abu-Raddad LJ, Chemaitelly H, Butt AA, et al. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385:187–189.
  • Liu C, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220–4236 e4213.
  • Scott L, et al. Track omicron's spread with molecular data. Science. 2021;374:1454–1455.
  • Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600:21.
  • Ai, J. et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern. Cell Res. 2022;32:103–106.
  • Hansen J, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010–1014.
  • Jones BE, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13: eabf1906.
  • Shi R, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584:120–124.
  • Pinto D, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290–295.
  • Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584:443–449.
  • Kim C, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021;12:288.
  • Rappazzo CG, et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371:823–829.
  • Liu L, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450–456.
  • Wang P, et al. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerg Microbes Infect. 2022;11:147–157.
  • Cerutti G, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021;29:819–833 e817.
  • Cerutti G, et al. Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. Cell Rep. 2021;37:109928.
  • Pulliam JRC, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. 2021. https://doi.org/10.1101/2021.11.11.21266068.
  • Burki, T. K. Omicron variant and booster COVID-19 vaccines. Lancet Respir Med. 2021. https://doi.org/10.1016/S2213-2600(21)00559-2
  • Ai J, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11:337–343.
  • Wang Y, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant omicron. Emerg Microbes Infect. 2022;11:1–5.
  • Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv. 2021. https://doi.org/10.1101/2021.12.12.472269
  • Zhang X, et al. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct Target Ther. 2021;6:430.
  • Doria-Rose NA, et al. Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization. medRxiv. 2021. https://doi.org/10.1101/2021.12.15.21267805
  • Andrews N, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv. 2021. https://doi.org/10.1101/2021.12.14.21267615
  • Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2021. https://doi.org/10.1038/s41586-021-04388-0
  • Planas D, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. Nature. 2021. https://doi.org/10.1038/s41586-021-04389-z
  • Cao Y, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2021. https://doi.org/10.1038/s41586-021-04385-3

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.